# MBX Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mbx-biosciences

- Industry: Biotechnology
- Headquarters: Carmel, US
- Website: www.mbxbio.com/
- Total disclosed funding: $136M
- Latest round: Series C (Aug 15, 2024)
- Investors on record: 12

## About

Based in the US, MBX Biosciences, Inc. specializes in the development of Precision Endocrine Peptide™ (PEP™) therapeutics designed to address endocrine and metabolic disorders, significantly enhancing patient treatment options.Founded in 2019, MBX Biosciences, Inc. is dedicated to advancing therapeutic candidates for endocrine and metabolic disorders. The company is headquartered in Carmel, US. In its path, MBX has successfully completed 6 deals, with the most recent deal occurring on September 12, 2024, during its SERIES C funding round, where it raised USD 63.50 mn led by Deep Track Capital. The total amount raised by the company is USD 63.50 mn, with a current valuation of USD 278.08 mn. Kent Hawryluk serves as the CEO of MBX Biosciences, Inc.MBX Biosciences, Inc. specializes in developing Precision Endocrine Peptide™ (PEP™) therapeutic candidates that focus on treating endocrine and metabolic disorders. The company is advancing a pipeline of peptide therapeutics aimed at improving treatment outcomes in conditions such as hypoparathyroidism and diabetes. These innovative products are designed to enhance pharmaceutical properties and address unmet clinical needs, with significant potential in the North American and European markets.MBX Biosciences generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies and healthcare institutions. Its business model relies on securing funding for research and development, as well as milestone payments linked to clinical trial achievements. Licensing agreements for its PEP™ therapeutics further contribute to revenue, targeting B2B transactions with biotech and healthcare providers. Notably, the company reported an EBITDA of USD -25.11 mn for the most recent year, 2022.On September 12, 2024, MBX Biosciences, Inc. raised USD 163.20 mn in an IPO, selling 10.2 million shares at USD 16 each on the Nasdaq Global Select Market under the ticker symbol "MBX". The company has initiated plans to expand its product offerings and enter new markets, with specific targets in regions like North America and Europe where there is significant demand for endocrine and metabolic disorder therapies. The recent funding will be utilized to support the development of upcoming PEP™ products and enhance clinical trial capabilities, capitalizing on the growing market opportunities.

## Funding rounds

- Series C, Aug 15, 2024, $64M — Frazier Healthcare Partners, New Enterprise Associates, OrbiMed Advisors, T Rowe Price, Norwest Venture Partners, Wellington Management, Driehaus Capital Management, RA Capital Management, Deep Track Capital
- Series B, Nov 7, 2022, $47M — Frazier Healthcare Partners, New Enterprise Associates, OrbiMed Advisors, Norwest Venture Partners, Wellington Management, RA Capital Management
- Series A, Jul 16, 2020, $26M — Frazier Healthcare Partners, New Enterprise Associates, OrbiMed Advisors, BioCrossroads, Twilight Venture Partners, IU Ventures

## Investors

- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B, Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- BioCrossroads (https://capitalatlas.ai/funds/biocrossroads) — Series A
- Twilight Venture Partners (https://capitalatlas.ai/funds/twilight-venture-partners) — Series A
- IU Ventures — Series A
- Norwest Venture Partners (https://capitalatlas.ai/funds/norwest-venture-partners) — Series B, Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series B, Series C
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Driehaus Capital Management (https://capitalatlas.ai/funds/driehaus-capital-management) — Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series C